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The July 2014 issue marks the halfway point for our editorial team’s tenure in
overseeing the scientiﬁc aspects of Diabetes Care. At this time in the process, we
would have thought that things would have become very routine. Speciﬁcally, one
might expect that changes made at the beginning of our term would now be
complete and we would be at a stage (to borrow a term from the aviation industry)
of “autopilot.” But, instead, we have realized that there is a new norm at the journal
. . . one that dictates a consistent principle . . . that Diabetes Care and its editorial
team continue to evolve!
For example, when we provided our update on the journal for July 2013, we titled
it “The Hits Just Keep on Coming!” (1). It was stated at the time: “To be honest,
I would be thrilled if, in January 2014, I can simply state we’ve had more of the
same!” Honestly, this is far from the truth. It has not been more of the same . . . we
have exceeded our own expectations! Over the last year, new initiatives have
continued, the number of new submissions is at record level, the quality of pub-
lished articles continues to increase, and our pleasure in seeing each and every
journal issue is heightened each month. It is ﬁtting at this halfway point to have
our editorial team collectively report on our further progress to you, the readers we
serve. From our perspective, this progress report is very appropriately titled as “It
Just Doesn’t Get Any Better . . . or Does It?”
To be fair, some of the developments from our team have been noted in past
editorials and are now considered as standard. For example, as you may well know
by now, our editorial team has initiated and reﬁned our Diabetes Care Symposium
at the American Diabetes Association’s (ADA’s) Scientiﬁc Sessions and recently
completed our third annual symposium. Those articles are featured in this issue
(2–5). Additionally, new formats were added to highlight dissemination of infor-
mation, e.g., Novel Communications in Diabetes reports (6). We continue to em-
phasize landmark studies sharing a speciﬁc focus in regular issues and continue to
place a prominence on publishing state-of-the-art reviews and summary state-
ments (7). We made a decision to require dual reporting of HbA1c in both % and
SI units that began 1 January 2013 (8). Finally, we continue to hold our Diabetes
Care Editors’ Expert Forum, generally held at the ADA’s Scientiﬁc Sessions, but at
other scientiﬁc meeting venues as well, and to publish the proceedings of the
forums. A recent forum on opportunities and challenges of insulin therapy in
type 2 diabetes, in addition to another forum on safety in general of all oral and
injectable diabetes agents, will appear in the next few months. Just recently, we
held an additional forum entitled “Hot Topics in Obesity” at the 74th Scientiﬁc
Sessions in San Francisco.
As has now become a tradition, the July issue features articles from our annual
Diabetes Care Symposium held each year at the Scientiﬁc Sessions; the most recent
was on 14 June 2014 in San Francisco. Now that the Symposium is an established
event, our goal is reﬁnement. This year we experimentedwith revising the format by
dividing it into two 1-h sessions and by selecting a predetermined umbrella topic.
The ﬁrst segment introduced a novel twist with a presentation entitled “Best of
Diabetes Care.” Its purpose was to provide brief overviews of several articles felt by
the Associate Editors to be some of the most noteworthy original research reports
published in Diabetes Care during the past year.
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The second segment presented four
outstanding symposium articles focus-
ing on “New Drug Therapies, Innovative
Management Strategies, and Novel
Drug Targets.” These selected ﬁnalists
included 1) a randomized control trial
evaluating the effect of canola oil on
glycemic control and cardiovascular
risk factors (2), 2) a report on the ﬁrst
randomized crossover trial of a wear-
able artiﬁcial pancreas (3), 3) a report
on the efﬁcacy of GLP-1 receptor ago-
nists in patients with maturity-onset
diabetes of the young (4), and 4) a con-
trolled trial of a new SGLT-2 inhibitor in
combination with insulin in obese inad-
equately controlled type 2 diabetes (5).
We look forward to continuing this new
format and to the 4th Annual Diabetes
Care Symposium at the 75th Scientiﬁc
Sessions scheduled for June 2015 in Bos-
ton, MA.
Another new initiative was our deci-
sion to devote a portion of selected is-
sues to a speciﬁc focus, either as
multiple reports from landmark studies
or to highlight a speciﬁc clinical and re-
search focus. We featured the TODAY
(Treatment Options for Type 2 Diabetes
in Adolescents and Youth) study in the
June 2013 issue of Diabetes Care (9).
This year, it was our privilege and honor
to celebrate the 30th anniversary of
the Diabetes Control and Complications
Trial (DCCT) and its follow-up study,
Epidemiology of Diabetes Interventions
and Complications (EDIC), by featuring
the 30th anniversary summary ﬁndings
in a special focus in the January 2014
issue (10). The articles from the special
DCCT/EDIC section provided an excel-
lent overview of the background and
outcomes of the study and were based
on presentations made at both the 2013
ADA Scientiﬁc Sessions and the 2013 Eu-
ropean Association for the Study of Di-
abetes (EASD) Annual Meeting (10). The
contributions summarized results to
date from the DCCT/EDIC for the major
complications of diabetes: neuropathy,
nephropathy, retinopathy, and cardio-
vascular disease.
Given the importance of the preven-
tion of diabetes, our editorial team as-
sembled articles on diabetes prevention
in the April 2014 issue of Diabetes Care
(11). The editorial team felt it was our
duty to keep the discussion on this im-
portant topic moving forward on this
issue by featuring these contributions.
Selected articles ranged from discussion
of genetic risk and progression to dia-
betes to policy development (12–16).
Importantly, the information was dis-
seminated with use of all of our formats,
including Novel Communications in Dia-
betes, Original Articles, Perspectives, and
Point-Counterpoint narratives.
Our most recent special focus section
was in the May 2014 issue, in which we
featured the most up-to-date collection
of articles on the artiﬁcial pancreas (17).
Speciﬁcally,we recognized the remarkable
progressmade todate in closed-loop tech-
nology with its safety and efﬁcacy re-
ported in both outpatient and inpatient
clinical trials. Therefore, given the in-
tense interest in this topic and its impor-
tance to clinical care, our editorial team
decided to publish a comprehensive se-
lection of articles devoted to the devel-
opment of the artiﬁcial pancreas,
including a two-part Bench to Clinic se-
ries, two randomized trials, and three
additional studies that provided new in-
formation on the technology (18–24).
In 2013, we also were honored to
publish important state-of-the-art Re-
views. These articles have included ex-
cellent updates on pancreas transplants
alone (25), inpatient management of di-
abetic foot disorders (26), and antide-
pressant medications as a risk factor
for type 2 diabetes (27) and a review
on barriers and potential solutions to
providing optimal guideline-driven care
from a diabetes working group reported
by Vigersky et al. (28).
Over the last few months, we have
had a reviewon targeting lipids in diabetic
pregnancy (29), an outstanding evalua-
tion of microalbuminuria as a risk predic-
tor in diabetes (30), and a comprehensive
and systematic review on pharmacoge-
netics of type 2 diabetes (31).
We continue to provide signiﬁcant in-
formation on translational medicine in
the form of Bench to Clinic narratives.
In this regard, our special feature on
closed-loop technology included a two-
part series featuring both the physiology
behind developing closed-loop systems
(18) and the engineering of the algo-
rithms (19). In addition, we featured
a cutting-edge review that outlined
mechanisms and management of pain-
ful diabetic distal symmetrical polyneu-
ropathy by Tesfaye et al. (32). Finally,
based on the crucial pathogenic role
of vascular endothelial growth factor
(VEGF) in the development of diabetic
macular edema, intravitreal anti-VEGF
agents have emerged as new treat-
ments. Therefore, we provided informa-
tion on the rationale for use and clinical
efﬁcacy of anti-VEGF treatment in a two-
part Bench to Clinic presentation with
contributions from Simo´ et al. (33) and
Cheung et al. (34).
One of our most popular formats con-
tinues to be the Point-Counterpoint ap-
proach. We published a well-received
two-part Point-Counterpoint narrative
on the validity of meta-analysis in diabe-
tes. Dr. Home (35) provided his opinion,
supported by a review of data, that we
should carefully evaluate meta-analyses
to assess the reliability of their conclu-
sions. In response, Drs. Golden and Bass
(36) emphasized that an effective sys-
tem exists to guide meta-analysis and
that rigorously conducted, high-quality
systematic reviews and meta-analyses
are an indispensable tool for synthesiz-
ing evidence despite their limitations.
One of the more intriguing Point-
Counterpoints our journal has ever pub-
lished appeared in the April 2014 issue
on diabetes prevention, focusing on
dietary sugar and the epidemic of obe-
sity and diabetes (37,38). The debate
centered on the controversy as to
whether sugar-sweetened drinks and
an overall increase of dietary intake of
glucose and high-fructose corn syrup
may be a major contributor to obesity
and the metabolic syndrome. Finally,
last month, we revisited the beneﬁt of
using analog insulins in clinical care by
providing a debate on “cost.”Dr. Davidson
(39), in a Counterpoint argument, took
the position that analog insulins pro-
vide no clinical beneﬁt compared with
human insulin, but cost much more.
Dr. Grunberger (40) provided a Point
argument in defense of analog insulins
and their value in clinical management
by suggesting that when one evaluates
“cost” of therapy, a much more global
assessment is needed.
Lastly, our Proﬁles in Progress cate-
gory, a narrative that speciﬁcally recogni-
zes a researcher or provider in the ﬁeld of
diabetes whose contributions and discov-
eries were noteworthy and remarkable,
continues to move forward. In the May
issue, we featured Dr. Gerald Reaven
whose lifelong work revolved around
the central role of insulin resistance in
type 2 diabetes and cardiovascular
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disease (41). We will continue to feature
pioneers in the diabetes ﬁeld.
In closing, our editorial team is hon-
ored to be serving its role in guiding
Diabetes Care at this time. We take
pride in every issue. We realize, and
have stated, that the journal will be
judged primarily on the quality of the
articles published. As an editorial
team, we take this charge seriously. As
such, given the diversity of interests of
the readers of Diabetes Care, it is a pri-
ority that we give full attention and con-
sideration to each and every manuscript
submitted. As such, expertise is required
for many different topics, and this is
achieved with comprehensive review
from the editorial team and our out-
standing reviewers. Clearly, the priori-
ties for Diabetes Care have increased,
and it is important that we keep the
hurdle high for eventual submission.
Given the remarkable quality of articles
published to date, we feel we are
achieving our goal. So, what can we ex-
pect as we move forward for the latter
half of our term? One would expect con-
tinuation of the new norm. Simply put,
we do not expect the day-to-day activi-
ties of the journal or the initiatives put
in place by the editorial team ever to
become routine. In this regard, beyond
rejoicing that it just doesn’t get any bet-
ter, we are also hoping that, in another
12months, we will still be asking, “Can it
possibly get any better than this?”
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